Risedronate Cuts Fracture Risk in Men with Parkinson's
Fractures down, bone mineral density up in patients receiving risedronate compared with placebo
TUESDAY, March 20 (HealthDay News) -- The bone resorption inhibitor, risedronate, can increase bone mineral density and reduce the risk of hip fracture in elderly men with Parkinson disease, according to a report in the March 20 issue of Neurology.
Yoshihiro Sato, M.D., of Mitate Hospital in Tagawa, Japan, and colleagues conducted a two-year, randomized, double-blind, placebo-controlled trial to determine if 2.5 mg risedronate plus vitamin D2 could help prevent osteoporosis and reduce the risk of hip fractures in elderly men with Parkinson disease. Overall, 121 patients each were randomized to risedronate and placebo.
The researchers found that nine patients in the placebo group and three patients in the treatment group experienced hip fracture during the study period leading to a relative risk reduction of 0.33. In addition, bone mineral density increased by 2.2 percent in the treatment group while decreasing by 2.9 percent in the placebo group. Measures of bone resorption improved in the treatment group, as well.
"Since serum 25-OHD is one of the major determinants of bone mineral density in patients with Parkinson disease, a therapy with vitamin D6 and risedronate may be more suitable for patients with Parkinson disease," the authors conclude. "However, calcium supplementation together with vitamin D should be avoided, since such therapy may further increase hypercalcemia."
The study was supported by Takeda Pharmaceutical Co., Ltd., Osaka, Japan.